keyword
MENU ▼
Read by QxMD icon Read
search

alopecia guidelines

keyword
https://www.readbyqxmd.com/read/29660422/cme-part-1-hair-disorders-in-cancer-patients
#1
REVIEW
Azael Freites-Martinez, Jerry Shapiro, Shari Goldfarb, Julie Nangia, Joaquin J Jimenez, Ralf Paus, Mario E Lacouture
Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders (including alopecia, hirsutism, hypertrichosis, pigmentary and textural hair changes). The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy -induced alopecia has been well-documented mainly in the oncology literature, however the effect of other alterations such as radiation-induced alopecia, hirsutism, changes in hair color or texture on quality of life have not been described...
April 13, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29603400/a-guide-to-studying-human-dermal-adipocytes-in-situ
#2
Carina Nicu, Jennifer Pople, Laura Bonsell, Ranjit Bhogal, David M Ansell, Ralf Paus
Dermal white adipose tissue (DWAT) is a main component of human skin, composed of individual lipid-laden mesenchymal cells known as dermal adipocytes (DAs). Besides their well-known role in lipid storage and release, DAs also promote skin immunity, wound healing and hair follicle cycling and are important players in cutaneous neuro-endocrinology. The ever-growing insights into DWAT functions, albeit mostly in mice, have invited speculation that it may be involved in multiple skin diseases ranging from fibrosis to alopecia and psoriasis, thus designating human DWAT a clinically relevant, but as yet insufficiently investigated skin compartment...
March 30, 2018: Experimental Dermatology
https://www.readbyqxmd.com/read/29528971/effects-of-5-alpha-reductase-inhibitors-new-insights-on-benefits-and-harms
#3
Joo Yong Lee, Kang Su Cho
PURPOSE OF REVIEW: The use of 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) and other diseases has been proposed and studied. However, the controversy about its benefits and harms for other diseases has persisted. In this review, we will discuss the newly identified effects of 5ARIs based on recently published studies. RECENT FINDINGS: These drugs are currently recommended in clinical guidelines for BPH. However, the reporting of adverse effects, including sexual dysfunction as well as neurologic, endocrine, and cardiovascular effects, have been controversial...
May 2018: Current Opinion in Urology
https://www.readbyqxmd.com/read/29478350/integrated-cancer-treatment-in-the-course-of-metastatic-pancreatic-cancer-complete-resolution-in-2-cases
#4
Massimo Bonucci, Carlo Pastore, Vincenzo Ferrera, Carla Fiorentini, Alessia Fabbri
Pancreatic cancer (PC) has a very low average survival, but its prognosis is further reduced in the case of metastatic spread. Medical therapy in these cases is the only applicable methodology in the international guidelines. During anticancer treatments, common side effects are nausea, vomiting, arthralgia, neuropathy, and alopecia as well as a myelosuppressive effect. The toxicity of various drugs not only affects the quality of life of the patient, but often its severity requires a reduction in if not the termination of drug administration...
February 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29128463/objective-outcome-measures-collecting-meaningful-data-on-alopecia-areata
#5
Elise A Olsen, Janet Roberts, Leonard Sperling, Antonella Tosti, Jerry Shapiro, Amy McMichael, Wilma Bergfeld, Valerie Callender, Paradi Mirmirani, Ken Washenik, David Whiting, George Cotsarelis, Maria Hordinsky
BACKGROUND: Although alopecia areata is a common disorder, it has no FDA approved treatment and evidence-based therapeutic data is lacking. OBJECTIVE: To develop guidelines for the diagnosis, evaluation, assessment, response criteria and endpoints for alopecia areata. METHODS: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. RESULTS: Standardized methods of assessing and tracking hair loss and growth including new scoring techniques, response criteria and endpoints in alopecia areata are presented...
November 8, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29105836/pediatric-severity-of-alopecia-tool
#6
Elena Bernardis, Jonathan Nukpezah, Ping Li, Theresa Christensen, Leslie Castelo-Soccio
The Severity of Alopecia Tool serves as a tool for alopecia research and a clinical guideline for following progression of disease. The original Severity of Alopecia Tool score does not take into account pediatric age groups. As new clinical trials for alopecia areata include more children, a more accurate tool should be available for this population. By collecting images from patients 2-21 years of age and aligning the hair-bearing regions of the scalp, we created an adaptation of the Severity of Alopecia Tool for scoring hair loss percentage of the top, parietal, and occipital scalp in individuals 2-5, 6-11, and 12-21 years of age...
January 2018: Pediatric Dermatology
https://www.readbyqxmd.com/read/29055953/an-open-label-randomized-multicenter-study-assessing-the-noninferiority-of-a-caffeine-based-topical-liquid-0-2-versus-minoxidil-5-solution-in-male-androgenetic-alopecia
#7
Rachita Dhurat, Jill Chitallia, Theodor W May, Ammani M Jayaraaman, Jithendriya Madhukara, Subbu Anandan, Pradyumna Vaidya, Adolf Klenk
BACKGROUND: Androgenetic alopecia is a condition with a high prevalence worldwide and affects both males and females. Currently, only 2 approved treatments exist: finasteride (males only) and minoxidil 2 or 5% solution (males and females). METHODS: We conducted a randomized, open-label, multicenter noninferiority study to determine whether a caffeine-based 0.2% topical liquid would be no less effective than minoxidil 5% solution in males (n = 210) with androgenetic alopecia...
2017: Skin Pharmacology and Physiology
https://www.readbyqxmd.com/read/28976026/scalp-hypothermia-as-a-preventative-measure-for-chemotherapy-induced-alopecia-a-review-of-controlled-clinical-trials
#8
REVIEW
V V Shah, T C Wikramanayake, G M DelCanto, C van den Hurk, S Wu, M E Lacouture, J J Jimenez
Chemotherapy-induced alopecia (CIA) is a temporary, yet psychologically devastating form of hair loss that affects 65% of patients receiving cancer chemotherapy. In the 1970s, scalp hypothermia was introduced as a preventative measure against the development of CIA. Numerous studies provide evidence for the effectiveness of scalp cooling to prevent CIA, although results varied because of differences in chemotherapy regimen, cooling technique, mode of administration and patient factors. However, many of the existing studies are uncontrolled or consist of small sample sizes, and data from randomized, randomized studies are limited...
October 4, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28973128/screening-guidelines-for-thyroid-function-in-children-with-alopecia-areata
#9
Deepa Patel, Ping Li, Andrew J Bauer, Leslie Castelo-Soccio
Importance: The incidence of thyroid disease in children with alopecia areata (AA) has been widely studied with no consensus on whether a true association with AA exists. In addition, screening practices for thyroid dysfunction in children with AA vary widely among clinicians. Objective: To reduce health care costs, eliminate unnecessary testing, and standardize clinical practices, we sought to characterize thyroid function in children with AA to establish guidelines for screening...
December 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28939291/scalp-hypothermia-for-preventing-alopecia-during-chemotherapy-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#10
Hope S Rugo, Jeffrey Voigt
BACKGROUND: Alopecia is a side effect of chemotherapy and affects a patient's quality of life. Cooling the scalp during chemotherapy might reduce alopecia. The objective of this systematic and meta-analysis was to examine the effects of scalp cooling on the end point of alopecia in randomized controlled trials. MATERIALS AND METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Electronic searches of databases were undertaken through February 2017...
February 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28748378/validation-of-an-egyptian-arabic-version-of-skindex-16-and-quality-of-life-measurement-in-egyptian-patients-with-skin-disease
#11
Nagwa Essa, Sara Awad, Mariam Nashaat
PURPOSE: To translate and cross-culturally adapt the Skindex-16, a brief skin-disease-specific QoL questionnaire, into Arabic for Egyptians and to evaluate its measurement properties in Egyptian patients with skin disease. METHOD: Translation and cultural adaption were performed following guidelines for cross-cultural adaption of health-related quality of life measures. Subsequently, Skindex-16 was administered to 500 consecutive dermatological patients and 500 healthy persons for verification of its reliability and validity...
July 26, 2017: International Journal of Behavioral Medicine
https://www.readbyqxmd.com/read/28716242/a-novel-pathogenic-variant-in-an-iranian-ataxia-telangiectasia-family-revealed-by-next-generation-sequencing-followed-by-in-silico-analysis
#12
Mohammad Amin Tabatabaiefar, Paria Alipour, Azam Pourahmadiyan, Najmeh Fattahi, Laleh Shariati, Neda Golchin, Javad Mohammadi-Asl
Ataxia telangiectasia (A-T) is a neurodegenerative autosomal recessive disorder with the main characteristics of progressive cerebellar degeneration, sensitivity to ionizing radiation, immunodeficiency, telangiectasia, premature aging, recurrent sinopulmonary infections, and increased risk of malignancy, especially of lymphoid origin. Ataxia Telangiectasia Mutated gene, ATM, as a causative gene for the A-T disorder, encodes the ATM protein, which plays an important role in the activation of cell-cycle checkpoints and initiation of DNA repair in response to DNA damage...
August 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28378336/review-of-treatment-for-alopecia-totalis-and-alopecia-universalis
#13
REVIEW
Sama Kassira, Dorota Z Korta, Lance W Chapman, Francis Dann
Alopecia areata (AA) is an autoimmune disease directed at the hair follicle. Although usually limited to patchy hair loss over the scalp (focalis), AA can present as total loss of scalp hair (totalis; AT) or as total loss of both scalp and body hair (universalis; AU). Management of AT and AU can be challenging, and although multiple treatment modalities have been explored, no therapy is currently FDA-approved. This review focuses on the evidence for current treatment options for AT and AU. The PubMed database was searched from January 1, 2000, to September 1, 2016, for clinical trials, retrospective studies, and case reports of treatments for AT and AU...
August 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28182134/differential-pharmacology-and-clinical-utility-of-sonidegib-in-advanced-basal-cell-carcinoma
#14
REVIEW
Mohd Wahid, Arshad Jawed, Sajad Ahmad Dar, Raju K Mandal, Shafiul Haque
Patients suffering from advanced basal cell carcinoma (BCC) have very limited treatment options. Sonidegib selectively inhibits the growth of Hedgehog pathway-dependent tumors and can treat locally advanced BCC patients who are not candidates for surgery or radiation therapy. The BOLT clinical trials were conducted to evaluate the efficacy/potency of sonidegib in the treatment of advanced BCC or metastatic BCC. The patients were randomized in 1:2 ratios to receive 200 or 800 mg oral sonidegib daily, stratified by disease, histological subtype and geographical region...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28150447/chemotherapy-induced-alopecia-management-clinical-experience-and-practical-advice
#15
Alfredo Rossi, Maria Caterina Fortuna, Gemma Caro, Giulia Pranteda, Valentina Garelli, Umberto Pompili, Marta Carlesimo
BACKGROUND: Chemotherapy-induced alopecia (CIA) is probably one of the most shocking aspects for oncological patients and underestimated by physicians. Among hair loss risk factors, there are treatment-related aspects such as drug dose, administration regimen, and exposure to X-rays, but also patient-related characteristics. To the best of our knowledge, no guidelines are available about CIA management. AIMS AND METHODS: With this study, based on literature background and our clinical experience, we would like to propose a list of actions in order to estimate the risk of hair loss before starting chemotherapy and to manage this condition before, during, and after drug administration and to create a sort of practical guide for dermatologists and oncologists...
December 2017: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/28094753/quantifying-cutaneous-adverse-effects-of-systemic-glucocorticoids-in-patients-with-rheumatoid-arthritis-a-cross-sectional-cohort-study
#16
MULTICENTER STUDY
Jonna Amann, Anne-Marie Wessels, Friederike Breitenfeldt, Dörte Huscher, Johannes W J Bijlsma, Johannes W G Jacobs, Frank Buttgereit
OBJECTIVES: EULAR guidelines state that adverse effects (AEs) of glucocorticoid (GC) therapy should be considered and discussed with the patient before treatment is initiated. However, reliable quantitative data, especially on cutaneous AEs of low-to-medium dose GCs are lacking. We performed a study assessing the occurrence of cutaneous AEs of GCs and its association with current and cumulative GC doses in patients with rheumatoid arthritis (RA). METHODS: In a cross-sectional study performed in 2 outpatient rheumatology centres, 381 RA patients were enrolled...
May 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27931749/-hereditary-epidermolysis-bullosa-french-national-guidelines-pnds-for-diagnosis-and-treatment
#17
C Chiaverini, E Bourrat, J Mazereeuw-Hautier, S Hadj-Rabia, C Bodemer, J-P Lacour
Hereditary epidermolysis bullosa (EB) is a heterogeneous group of rare genetic diseases characterized by fragile skin and/or mucous membrane, and it may be either local or generalized. It is caused by mutations in genes encoding different proteins involved mainly in the structure and function of the dermal-epidermal junction. Nineteen genes have so far been identified. They are classified by level of skin cleavage (from top to bottom) into four groups: EB simplex, junctional EB, dystrophic EB and Kindler syndrome...
January 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/27789379/a-new-label-free-screen-for-steroid-5%C3%AE-reductase-inhibitors-using-lc-ms
#18
Jukkarin Srivilai, Karma Rabgay, Nantaka Khorana, Neti Waranuch, Nitra Nuengchamnong, Kornkanok Ingkaninan
Steroid 5α-reductase (S5αR) plays an important role in metabolizing testosterone into active androgen dihydrotestosterone (DHT) which is involved in many androgen dependent disorders, such as androgenic alopecia, benign prostatic hyperplasia and acne. The method for screening for S5αR inhibition is key in finding new antagonists. In this study, the label-free S5αR inhibitory assay using LC-MS was developed. S5αR type 1 enzyme was obtained from LNCaP prostate cancer cells. The enzymatic assay was optimised for enzyme-substrate (testosterone) concentration, NADPH-cofactor concentration, solvent tolerance, enzyme activity stability and incubation time...
December 2016: Steroids
https://www.readbyqxmd.com/read/27601857/female-pattern-hair-loss-a-retrospective-study-in-a-tertiary-referral-center
#19
Tee Wei Siah, Llorenia Muir-Green, Jerry Shapiro
BACKGROUND: Female pattern hair loss (FPHL) is a very common problem in women. The underlying pathophysiology remains unclear, and there are no universally agreed treatment guidelines. OBJECTIVE: We explored the clinical features, relevant medical and family history, laboratory evaluation, and treatment and compliance of 210 patients with FPHL. METHODS: Data analysis from case notes was performed on 210 patients with a diagnosis of FPHL seen from January 2011 to December 2011...
April 2016: International Journal of Trichology
https://www.readbyqxmd.com/read/27581783/adverse-effects-of-voriconazole-over-a-decade-of-use
#20
REVIEW
Miriam T Levine, Pranatharthi H Chandrasekar
Voriconazole use has increased since the drug's introduction in 2002, and new and unique adverse effects are emerging as patients undergo prolonged therapy. Most concerning is the increased risk of cutaneous malignancies, primarily squamous cell carcinoma (SCC); this risk is duration dependent and the associated malignancies tend to be more aggressive and multifocal. Voriconazole is also associated with phototoxicity (which may be a precursor to malignancy), periostitis, hallucinations and encephalopathy, peripheral neuropathy, alopecia, nail changes, hyponatremia, and other adverse effects...
November 2016: Clinical Transplantation
keyword
keyword
75159
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"